Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kura Oncology (KURA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 616,975
  • Shares Outstanding, K 33,350
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,430 K
  • 36-Month Beta 4.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.02

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.50 +19.35%
on 06/04/18
19.15 -3.39%
on 06/20/18
+1.50 (+8.82%)
since 05/22/18
3-Month
14.60 +26.71%
on 04/26/18
19.90 -7.04%
on 03/27/18
-0.60 (-3.14%)
since 03/22/18
52-Week
5.90 +213.56%
on 08/18/17
24.02 -23.00%
on 02/20/18
+10.60 (+134.18%)
since 06/22/17

Most Recent Stories

More News
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial

- John Farnam appointed to newly created position of Chief Operating Officer -

KURA : 18.50 (-0.54%)
Kura Oncology to Present at JMP Securities Life Sciences Conference

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., Kura's President...

KURA : 18.50 (-0.54%)
OncoDNA announces screening collaboration with Kura Oncology

- OncoDNA to support patient enrolment for Kura Oncology's Phase II trial of tipifarnib

KURA : 18.50 (-0.54%)
Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update

- Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) on track to initiate in second half of 2018 -

KURA : 18.50 (-0.54%)
Kura Oncology to Present at Deutsche Bank 43rd Annual Health Care Conference

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Deutsche Bank 43rd...

KURA : 18.50 (-0.54%)
DB : 11.01 (+1.10%)
Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies

- Newly issued patent expands protection for tipifarnib in U.S., provides exclusivity in certain CXCL12-expressing cancers to 2037 -

KURA : 18.50 (-0.54%)
Kura Oncology to Report First Quarter 2018 Financial Results

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2018 financial...

KURA : 18.50 (-0.54%)
Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that three abstracts relating to the company's...

KURA : 18.50 (-0.54%)
Kura Oncology to Present at Oppenheimer 28th Annual Healthcare Conference

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Oppenheimer 28th Annual...

KURA : 18.50 (-0.54%)
Today's Research Reports on Trending Tickers: Kura Oncology and Zynerba Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / March 13, 2018 / U.S. markets were mixed Mondays as concerns over a potential trade war overshadowed Friday's jobs data. The Dow Jones Industrial Average declined 0.62 percent...

KURA : 18.50 (-0.54%)
ZYNE : 11.57 (-6.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade KURA with:

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

2nd Resistance Point 19.13
1st Resistance Point 18.82
Last Price 18.50
1st Support Level 18.17
2nd Support Level 17.83

See More

52-Week High 24.02
Last Price 18.50
Fibonacci 61.8% 17.10
Fibonacci 50% 14.96
Fibonacci 38.2% 12.82
52-Week Low 5.90

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar